News

Filter

176 to 185 of 96977 results

Par Pharmaceuticals receives FDA approval for Vasostrict in low blood pressure

Par Pharmaceuticals receives FDA approval for Vasostrict in low blood pressure

13-11-2014

Generic and branded specialty pharma company Par Pharmaceuticals has received approval for its New Drug…

HematologyPar PharmaceuticalsPharmaceuticalRegulationUSAVasostrict

Ulcerative colitis market to hit $4.2 billion by 2023

Ulcerative colitis market to hit $4.2 billion by 2023

13-11-2014

The ulcerative colitis market is set to grow from $2.7 billion in 2013 to $4.2 billion in 2023 in the…

Decision Resources GroupEntyvioGastro-intestinalsGlobalMarkets & MarketingPharmaceuticalRemicadeResearchXeljanz

Merck KGaA raises forecasts on solid third-quarter 2014

Merck KGaA raises forecasts on solid third-quarter 2014

13-11-2014

German pharma and chemicals firm Merck KGaA this morning reported that revenue for the third quarter…

FinancialGermanyMerck KGaAMerck SeronoPharmaceutical

SMC accepts Eylea and Onglyza for use in NHS Scotland

SMC accepts Eylea and Onglyza for use in NHS Scotland

13-11-2014

The Scottish Medicines Consortium (SMC) has accepted German drugmaker Bayer’s Eylea (aflibercept solution…

AstraZenecaBayerDiabetesEyleaOnglyzaPharmaceuticalRegulationUK

UPDATE: UK agrees “Patent Box” compromise with Germany

UPDATE: UK agrees “Patent Box” compromise with Germany

13-11-2014

Germany and the UK have agreed a joint proposal to advance the negotiations on new rules for preferential…

FinancialGermanyPatentsPharmaceuticalPoliticsUK

Boehringer Ingelheim drops option for Athera’s PC-MAb

12-11-2014

Sweden’s Athera Biotechnologies, which is 65% owned by Karolinska Development, says that German family-owned…

Athera BiotechnologiesBiotechnologyBoehringer IngelheimCardio-vascularLicensing

GlaxoSmithKline files for added Revolade indication in EU

12-11-2014

UK pharma major GlaxoSmithKline has filed an application with the European Medicines Agency for a variation…

EuropeGlaxoSmithKlineLigand PharmaceuticalsOncologyPharmaceuticalPromactaRare diseasesRegulationRevolade

UK health system spends most on AbbVie's Humira overall, according to HSCIC data on prescribing habits

UK health system spends most on AbbVie's Humira overall, according to HSCIC data on prescribing habits

12-11-2014

The Health & Social Care Information Centre has published its report on the prescribing habits of the…

HumiraLucentisMarkets & MarketingNational Health ServicePharmaceuticalResearchUKUnited Kingdom

Boehringer Ingelheim start Phase III trial on idarucizumab as antidote to Pradaxa

Boehringer Ingelheim start Phase III trial on idarucizumab as antidote to Pradaxa

12-11-2014

German family-owned drug major Boehringer Ingelheim has initiated a global Phase III study on idarucizumab,…

Boehringer IngelheimHematologyidarucizumabPharmaceuticalPradaxaResearch

176 to 185 of 96977 results

Parexel

Parexel

Back to top